Diffusion Pharmaceuticals...

NASDAQ: DFFN · Real-Time Price · USD
4.40
0.41 (10.28%)
At close: Aug 16, 2023, 10:00 PM

Company Description

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen.

Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease.

Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.

Diffusion Pharmaceuticals Inc.
Diffusion Pharmaceuticals Inc. logo
Country United States
IPO Date May 23, 2008
Industry Biotechnology
Sector Healthcare
Employees 13
CEO Robert J. Cobuzzi Jr.,

Contact Details

Address:
300 East Main Street
Charlottesville, Virginia
United States
Website https://www.diffusionpharma.com

Stock Details

Ticker Symbol DFFN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001053691
CUSIP Number 253748305
ISIN Number US15713L1098
Employer ID 30-0645032
SIC Code 2834

Key Executives

Name Position
Dr. Robert J. Cobuzzi Jr., Ph.D. Pres & Chief Executive Officer
William Karl Hornung Chief Financial Officer
Brian D. Bollwage Senior Consultant - Regulatory Affairs
Douglas Gravatt Senior Consultant for Manufacturing
Dr. Christopher D. Galloway M.D. Chief Medical Officer
Dr. David Randolph Jones M.D. Senior Medical Advisor
Dr. Jennifer Llewelyn Ph.D. Senior Director & Head of CMC
Harry Cook Vice President of Clinical Operations
Kelly Hoy Director of Project Management
Raven Jaeger M.S. Chief Regulatory Officer
Suzanne Cassidy Senior Director & Head of Quality Assurance
William Robert Elder J.D. Gen. Counsel & Corporation Sec.

Latest SEC Filings

Date Type Title
Aug 14, 2025 SCHEDULE 13G/A [Amend] Filing
Aug 11, 2025 8-K Current Report
Aug 08, 2025 10-Q Quarterly Report
Aug 05, 2025 8-K Current Report
Jul 28, 2025 8-K Current Report
Jun 25, 2025 8-K Current Report
Jun 25, 2025 4 Filing
Jun 25, 2025 4 Filing
Jun 25, 2025 4 Filing
Jun 25, 2025 4 Filing